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Abstract 
 
THE ROLE OF BETA2 SUBUNIT CONTAINING NICOTINIC ACETYLCHOLINE 
RECEPTORS ON ANXIETY-LIKE BEHAVIOR: A STUDY IN FEMALE MICE 
By Jessicka Hall, B.Sc. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master 
of Science, at Virginia Commonwealth University.  
Virginia Commonwealth University, 2012.  
Advisor:  Darlene H. Brunzell, Ph.D., Dept of Pharmacology and Toxicology 
Tobacco dependence is high in women who suffer from anxiety disorders yet 
little is known about the contributions of nicotinic acetylcholine receptors (nAChRs) 
on anxiety-like behavior. β2*nAChRs (*denotes assembly with other subunits) are 
the most abundantly expressed nAChRs in the brain yet little is known about the 
contributions of β2*nAChRs on anxiety-like behavior in female mice. In this study, 
antagonism and nicotine effects on anxiety-like behavior was investigated across the 
life span in 6, 12 and 24-month-old drug-naïve knockout (KO), heterozygous (HET) 
and a gain of function α6L9S mice and wild type (WT). HET mice showed increased 
sensitivity to di-hydrobeta-erythroidine compared to WT mice. Aged mice showed 
decreased locomotor activity and exploratory behavior compared to younger mice. 
Low doses of nicotine produced anxiolytic-like effects, whilst a high dose of nicotine 
produced anxiogenic-like effects. Activation of the α6*nAChRs supports an 
anxiolysis-like phenotype. These results implicate α4β2*nAChRs and α6β2*nAChRs 
in anxiety-like behavior.  
  
 
1 
Introduction 
 
Anxiety disorders are a major public health concern. In the United States, 
alone, tens of millions of people are affected by a range of clinically diagnosed 
anxiety disorders. It is estimated that 25% of all American adults have suffered from 
mental illness and nearly 50% of Americans will develop at least one mental illness 
during their lifetime (CDC, 2011a). Anxiety disorders are expensive to treat. The 
Agency for Healthcare Research and Quality’s (AHR’s) has reported that the annual 
costs associated with mental health in 2006 in the United States were over $57 
billion.  Despite the healthcare dollars spent on this disorder, a majority of individuals 
with anxiety disorder are unresponsive to traditional treatment (Koen & Stein, 2011), 
indicating a need for novel therapeutics.  This thesis will focus on nicotinic 
acetylcholine receptor subunit contributions to anxiety-like behavior in rodents. 
Understanding the molecular underpinnings of anxiety-like behavior may lead to 
more successful treatments for anxiety disorders and related health concerns.  
 
Anxiety and Tobacco Use 
There are approximately 6 million annual tobacco-related deaths worldwide, 
all of which are preventable (World Health Organization, (MMWR, 2008). For many, 
anxiety disorders are also associated with nicotine dependence. Of the 6 billion 
smokers worldwide, subsets of these smokers suffer from psychiatric disorders (J. R. 
Hughes, Hatsukami, Mitchell, & Dahlgren, 1986; Kalman, Morissette, & George, 
2005). Research has shown that people who suffer from anxiety disorders are twice 
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likely to smoke (Lasser et al., 2000), suggesting that individuals with anxiety may be 
more vulnerable to tobacco dependence The National Comorbidity Survey (NCS) 
has reported a greater prevalence of nicotine dependence among patients who 
suffer from any anxiety disorders than among the general population (SAMHSA, 
2004). Patients who suffer from anxiety and depression disorders have reported that 
they smoke to improve their symptoms of anxiety, mood and depression or to self-
medicate (Kassel, Stroud, & Paronis, 2003; Khantzian, 1997). Anxiety is also an 
important factor in the psychopathology of schizophrenia where individuals have a 
four-fold elevated risk for smoking (Court et al., 2000; J. R. Hughes, Hatsukami, 
Mitchell, & Dahlgren, 1986).  In addition to using tobacco to self-medicate symptoms 
of their disorders, those who suffer from mental illness may also have a shared 
vulnerability for their psychiatric and tobacco dependence (Khantzian, 1997; 
Morisano, Bacher, Audrain-McGovern, & George, 2009).    
Research has shown that there is an increase in nicotine dependence and 
substance abuse amongst sufferers of psychiatric disorders (Kalman, Morissette, & 
George, 2005; Markou, Kosten, & Koob, 1998). Not surprisingly, studies have 
demonstrated that patients who suffer from anxiety and depression disorders have 
reported that they smoke to self-medicate and to improve their symptoms of anxiety, 
mood and depression (Kassel, Stroud, & Paronis, 2003; Khantzian, 1997). Nicotine 
is the major psychoactive ingredient in tobacco and is an agonist at nicotinic 
acetylcholine receptors (nAChRs) in the CNS and periphery(J. P. Changeux, 
Devillers-Thiery, & Chemouilli, 1984; J. P. Changeux et al., 1998; J. P. Changeux, 
2010; M. R. Picciotto, 1998). Cigarette smoking is the leading preventable cause of 
death in developed countries and a major health concern in those with anxiety 
disorder who have twice the risk of tobacco dependence (Kalman, Morissette, & 
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George, 2005). The mechanisms involved in the anxiolytic effects of nicotine are not 
well understood. Therefore, using genetic and pharmacological tools, the aim of this 
thesis work is to elucidate the molecular mechanisms by which nicotine carries out 
its anxiolytic effect in mice.  
 
Nicotinic Acetylcholine Receptors and Anxiety 
This thesis will investigate the contributions of high affinity nAChRs to 
affective behaviors in female mice.  Nicotine is a major psychoactive ingredient in 
tobacco that acts on the brain centers associated with anxiety disorders by binding to 
nAChRs.  nAChRs are ion channels located on the plasma membrane of neurons; 
when activated by nicotine or the endogenous ligand acetylcholine (ACh), nAChRs 
become permeable to cations that excite the cell. Nicotine competes with ACh for 
activation of the receptor. Animal and human studies have shown that nicotine’s 
ability to reduce symptoms of anxiety is dose dependent (Juliano, Fucito, & Harrell, 
2011; K. A. Perkins et al., 2006; M. R. Picciotto, Brunzell, & Caldarone, 2002). 
Nicotine binds to various central nervous system (CNS) nAChR subtypes and the 
subsequent release of neurotransmitters associated with emotional states relating to 
anxiety disorders is critical for the modulation of the symptoms of anxiety. This thesis 
will use mouse models to test the hypothesis that nicotinic receptors that contain a 
β2 subunit (β2*nAChRs; *denotes assembly with other subunits) regulate anxiety-like 
behavior in females.   
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Neuronal Nicotinic Acetylcholine Receptors 
  nAChRs is a cholinergic receptor that belongs to the cys-loop receptor 
superfamily of ligand-gated ion channels. Cys-loop receptors have a canonical 13 
amino-acid motif commonly flanked by a disulphide bridge. The receptor channel 
complex has a pentameric structure made up of 5 nicotinic subunits that form a 
central pore or channel through which cations flow. Each subunit is composed of 4 
different membrane-spanning regions.  The nAChR protein was initially identified as 
a protein from fish electric organ as a heteropentamer of about 300 000 MW with a 
(α12, β1, γ1, δ1) stoichiometry (J. P. Changeux et al., 1998). Further investigation has 
shown that this single molecular species carries two ACh binding sites located at 
interfaces between subunits; it has an ion channel along its transmembrane axis of 
pseudo-symmetry, and all the structural elements that mediate their coupling in the 
course of the activation and desensitization processes. Unlike peripheral nAChRs, 
which are found predominantly at the postsynaptic terminals of the neuromuscular 
junction, nAChRs in brain predominate on the soma and terminals of neurons where 
they modulate neurotransmitter release (for review see (J. P. Changeux et al., 1998). 
Currently, the sequences of 12 neuronal nAChR subunits have been established in 
brain (Corringer, Le Novere, & Changeux, 2000; McGehee & Role, 1995) nine are 
designated as α-subunits (α2–α10) and share with electric organ α1 subunit a pair of 
adjacent cystisines, while the others are referred to as non-α or β-subunits (β2–β4). 
All nAChR subunits share a similar hydropathy profile, consisting of a large globular 
extracellular N-terminal hydrophilic domain that carries the multiple loops and the 
neurotransmitter binding site, a trans-membrane domain made of four α-helices (M1 
to M4) about 20 amino acids long that defines the ion channel, and a cytoplasmic 
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domain. The cytoplasmic domain is inserted between the M3 and M4 and is believed 
to contribute to the anchoring of the receptor to the plasma membrane and to the 
modulation of the channels activity (J. P. Changeux et al., 1998).  
The nAChRs are pentameric oligomers that undergo transitions for activation 
and desensitization. Investigation of the sequence of the known nAChR subunits 
indicates that these subunit genes share a common origin and have a long 
phylogenetic history. However, noticeable differences exist in the structure and 
variety of assembly of their subunits, their physiological and pharmacological 
properties, and their distribution in the brain (J. P. Changeux, Devillers-Thiery, & 
Chemouilli, 1984; J. P. Changeux et al., 1998; J. P. Changeux, 2010). Various 
combinations of both α-type and β-type subunits form a wide variety of functional 
heterooligomers, with two (α2β2, α3β2, α4β2, α3β4, α6β2 etc.) or more (α3β4α5) 
(α1β2α5), (α3β2β4α5) different subunits. These various combinations of nAChR 
subunits produce nAChRs with distinct pharmacological and physiological properties. 
The nAChRs containing the α and β subunits are the most abundantly 
expressed nAChRs in the central nervous system. Immunoprecipitation of rat brain 
tissue suggest that the α4 and β2 subunits co-assemble with each other and not with 
the α7 subunit (Flores, Rogers, Pabreza, Wolfe, & Kellar, 1992; Sargent, 1993; 
Zwart & Vijverberg, 1998).  Immunoprecipitation studies of have shown that nAChRs 
containing α4 and β2 subunits account for a majority of the high-affinity 3H-nicotine 
and 3H-cytisine (for the α4 nAChR) binding sites in rat brain (Flores, Rogers, 
Pabreza, Wolfe, & Kellar, 1992; Sargent, 1993; Zwart & Vijverberg, 1998). Studies 
with α-bungarotoxin a neurotoxic protein that binds competitively and irreversibly to 
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α7 but not α4 and β2 nAChRs shows that the α7 is the next largely distributed 
nAChRs to those that contain the α4 and β2 (Flores, Rogers, Pabreza, Wolfe, & 
Kellar, 1992; Sargent, 1993; Zwart & Vijverberg, 1998). The α7 nAChR has a lower 
affinity for agonists such as nicotine and ACh (for review see (McGehee & Role, 
1995)). The affinity binding of agonists such as nicotine and cytisine as well as 
α-bungarotoxin binding are similar to those seen in human post mortem brain 
(Breese, Adams et al., 1997; Breese, Marks et al., 1997).  
Nicotine can exert its effects by activation or desensitization of the nAChR. 
Activation of the nAChR leads to changes in behavior, similarly desensitization of the 
receptor can lead to a disruption of the transmission of endogenous ACh and the 
subsequent change in neuronal function that also leads to behavioral changes (for 
review see (M. R. Picciotto, Addy, Mineur, & Brunzell, 2008). It is therefore important 
to investigate the behavioral effects mediated by the activation or desensitization of 
high the affinity nAChRs by nicotine. 
It is not clear if nicotine regulates its effects on anxiety via activation or 
desensitization of the nAChRs.  Animal research has shown that nicotine’s activity at 
nAChRs is dose dependent and rewarding doses of nicotine activate nAChRs 
followed by rapid desensitization (J. P. Changeux et al., 1998; M. R. Picciotto, 
Brunzell, & Caldarone, 2002; M. R. Picciotto, Addy, Mineur, & Brunzell, 2008). 
Previous work has shown that sub-activating concentrations of nicotine reduces 
GABA release following nicotine pre-treatment (Lu, Marks, & Collins, 1999). Also, 
research has shown that chronic nicotine exposure results in an up-regulation of 
nAChRs (Kobiella et al., 2011; Lopez-Hernandez et al., 2004; Lukas, 1991; M. R. 
Picciotto, Brunzell, & Caldarone, 2002; M. R. Picciotto, Addy, Mineur, & Brunzell, 
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2008) and following chronic administration of nicotine a loss of nicotinic receptor 
functional activity occurs as a result of rapid and persistent desensitization (Eilers, 
Schaeffer, Bickler, & Forsayeth, 1997; Fenster, Rains, Noerager, Quick, & Lester, 
1997; Hsu, Amin, Weiss, & Wecker, 1996; Katz & Thesleff, 1957; J. Lasalde-
Dominicci et al., 2004; M. J. Marks, Farnham, Grady, & Collins, 1993; Peng, 
Gerzanich, Anand, Whiting, & Lindstrom, 1994; Sharp & Beyer, 1986; Vibat, Lasalde, 
Mcnamee, & Ochoa, 1995). This desensitized state has a higher affinity for 
acetylcholine and this state favors the anxiolytic-like effects of nicotine, research has 
shown that nAChRs desensitize with prolonged exposure to agonists with varying 
kinetics (J. P. Changeux, Devillers-Thiery, & Chemouilli, 1984; D. K. Williams, Wang, 
& Papke, 2011). Desensitization depends on concentration and exposure of agonists 
where long exposure leads to prolonged states that recover more slowly (Girod and 
Role, 2001). Similarly in human imaging studies, smoking of 2.4 cigarettes to satiate 
resulted in the occupancy of 80% receptors for up to 5 hours (Esterlis et al., 2010). 
This thesis will investigate the role the high affinity nAChRs play in nicotine- 
mediated anxiety behavior. 
 
High Affinity Nicotinic Receptors 
The β2*nAChRs, (i.e. α4β2, α6α4β3, α4α5β2) make up a subclass of 
nAChRs to which nicotine binds with high affinity (Flores, Rogers, Pabreza, Wolfe, & 
Kellar, 1992; Sargent, 1993; Zhou et al., 2003; Zwart & Vijverberg, 1998) β2*nAChR 
has been found to be important for nicotine reward (Brunzell et al., 2006; Brunzell, 
Boschen, Hendrick, Beardsley, & McIntosh, 2010; Brunzell, 2012; Corrigall, Franklin, 
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Coen, & Clarke, 1992; De Biasi & Dani, 2011; Gotti et al., 2010; Jackson, McIntosh, 
Brunzell, Sanjakdar, & Damaj, 2009; M. R. Picciotto et al., 1998; Pons et al., 2008; 
Tapper et al., 2004). β2 knockout mice do not express conditioned place preference 
to nicotine and β2 subunit knockout mice self-administer cocaine but fail to maintain 
self-administration when the cocaine is switched to nicotine (Jackson, Walters, & 
Damaj, 2009; M. R. Picciotto et al., 1998). This suggests that β2*nAChRs are 
necessary for the maintenance of nicotine self-administration (M. R. Picciotto et al., 
1998). Additionally, animals will self-administer a selective agonist of β2*nAChRs, 
suggesting that activation of these receptors is sufficient for nicotine self-
administration (Liu et al., 2003). Other studies suggest that the α4 and α6 subunits 
that partner with β2 are also critical for nicotine conditioned place preference and 
nicotine self-administration (Avale et al., 2008; Brunzell, Boschen, Hendrick, 
Beardsley, & McIntosh, 2010; Brunzell, 2012; Gotti et al., 2010; Jackson, McIntosh, 
Brunzell, Sanjakdar, & Damaj, 2009; McGranahan, Patzlaff, Grady, Heinemann, & 
Booker, 2011; Orejarena et al., 2012), (Brunzell et al., 2006; Brunzell, Boschen, 
Hendrick, Beardsley, & McIntosh, 2010; Brunzell, 2012; Corrigall, Franklin, Coen, & 
Clarke, 1992; De Biasi & Dani, 2011; Exley et al., 2011; Gotti et al., 2010; Jackson, 
McIntosh, Brunzell, Sanjakdar, & Damaj, 2009; M. R. Picciotto et al., 1998; Pons et 
al., 2008; Tapper et al., 2004). Compared to wild type mice, α4 and β2 KO mice do 
not show an increase in striatal DA levels in response to nicotine, supporting the idea 
that α4β2* nAChRs are necessary for dopamine release (L. M. Marubio et al., 2003; 
M. R. Picciotto et al., 1998), a nicotinic response that is believed to be involved in 
dependence.  
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The β2*nAChRs have also been found to play a role in the anxiolytic effect of 
nicotine (Besson, Suarez, Cormier, Changeux, & Granon, 2008; King, Caldarone, & 
Picciotto, 2002; Labarca et al., 2001; McGranahan, Patzlaff, Grady, Heinemann, & 
Booker, 2011). The use of transgenic mice for the characterization of each subunit’s 
role in nicotine’s mediated response is extensive. Research has shown that 
homozygous mutant mice for the α4 subunit showed increased basal levels of 
anxiety, which was attenuated by nicotine in the plus maze (Ross et al., 2000). In 
this study cDNA probe encoding the putative second transmembrane domain of the 
α4 nAChR receptor subunit was cloned by PCR amplification of embryonic stem 
(ES) cell-derived genomic DNA using primers based on conserved regions between 
the human and rat published cDNA sequence.  Studies by McGranhan and 
colleagues (2011) show that a low dose of nicotine elicited anxiolytic response in the 
elevated plus maze as shown by increases in the time spent in the open arms. This 
effect was not observed in a4 nAChR subunit knockout mice.  Labarca et al., 2001 
also show that mice heterozygous for a gain of function single point mutation in their 
α4 nAChR subunit had increased anxiety behavior compared to wild type controls as 
measured by a decrease in open arm activity on the elevated plus maze. This 
highlights the importance of the α4*nAChR receptor subunit in anxiety behavior. 
Little is known about the role that α6*nAChRs play in anxiety behavior. The 
α6 subunit is a ligand binding subunit that co-assembles with the α4-, β2- and β3- 
subunits. The α6*nAChRs are highly selectively expressed in DA neurons and is 
also found in the locus coeruleus and retinal ganglion cells and have the highest 
sensitivity to nicotine and ACh as shown by a 100-fold increase in EC50 value of 
α6*nAChRs versus control (Salminen et al., 2007). These receptor subtypes are key 
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players in the cholinergic control of DA release. In contrast to knockout mutant mice, 
mutant strains have been generated that have a gain of function at the α6 subunit. A 
mouse line the α6L9S has been generated in which a bacterial artificial chromosome 
(BAC) transgene was transfected into the mouse germline with a mutant copy of the 
mouse Chrna6 gene that rendered mutant α6* channels “hypersensitive” to 
endogenous ACh or exogenous nicotine. This resulted in the augmentation of DA 
neuron excitability and DA release in response to nicotine in these mice (Drenan et 
al., 2008). In this thesis α6L9S mice will be used to assess the role the α6 subunit 
plays in anxiety behavior.  
Chronic exposure to oral nicotine in female C57Bl/6 mice resulted in tolerance 
to the locomotor depressant and hypothermic actions of acute nicotine challenge. 
This tolerance was associated by an increase in β2*nAChR (i.e. α4β2, α6α4β3, 
α4α5β2) and α7nAChR number assessed by autoradiography techniques using 3H-
cytisine and 125I- α-bungarotoxin as radioligands (Sparks & Pauly, 1999).  In 
contrast, a preponderance of the evidence shows that α6*nAChR binding is 
decreased by chronic nicotine exposure (Champtiaux et al., 2002). Taken together, 
these results indicate that following chronic administration of nicotine there is change 
in the balance of high affinity nAChRs that may contribute to nicotine dependence 
and alter the effects mediated by nicotine.   
It is important to note that nAChRs do not act alone and their function in the 
broader genetic context of multiple genes and biological cascades must also be 
considered. Some caution is needed for the interpretation of the results of studies 
using transgenic mice. nAChRs are expressed during embryogenesis and there is a 
  
 
11 
possibility that developmental compensation may occur either in the expression of 
other nAChR subunits or in related neurotransmitters. It is also important to note that 
there are behavioral differences that exist between mouse strains and when 
transgenic mice are used to investigate receptor function, mutations, unlike receptor 
agonists and antagonists, cannot be easily overcome in an in vivo preparation to 
provide a direct before-and- after comparison within the same organism. 
Nevertheless, transgenic animals allow us to observe the function of specific genes 
in the complex environment of a living organism, and transgenic techniques usefully 
complement traditional approaches.  
 
Sex differences in high affinity nAChR expression 
Sex differences in the availability of high affinity nAChRs containing the β2 
subunit have been shown in smokers following abstinence. Using 123I-5-iodo-A-
85380 single photon emission computed tomography to measure the availability of 
β2*nAChRs showed that male smokers showed greater availability compared to 
male non-smokers. This effect, however was absent in female smokers, female 
smokers did not show any difference compared non-smoking females.  
Animal research has shown that chronic nicotine exposure in females has 
been found to results in increased anxiety-like behavior. However, in males, chronic 
nicotine administration results in decreased anxiety-like behavior (Caldarone, King, & 
Picciotto, 2008). It is unknown whether this may be due in part to changes in 
expression of β2*nAChRs. Our lab has shown that antagonism of the β2*nAChRs 
(i.e. α4β2, α6α4β3, α4α5β2) with the selective antagonist of β2*nAChRs, DHβE, 
supports anxiolytic-like behavior in male C57BL/6 mice (unpublished findings). This 
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thesis work will use combine pharmacological and genetic approaches to explore 
how inactivation of the β2*nAChRs affects anxiety-like behavior in female mice. 
 
Sex as a determinant for smoking behavior 
There are great costs associated with cigarette smoking. Cigarette smoking 
accounts for 1 in 5 deaths in the United States each year.  Cigarette use is more 
common in men (21.5%) than women (17.3 %) (CDC, 2011b), but tobacco related 
deaths in women have increased steadily over the past 10 years (K. A. Perkins, 
Donny, & Caggiula, 1999; Wetter et al., 1999). Women who smoke are more likely 
than men to report that smoking cigarettes relieves anxiety (Marqueta, Nerin, 
Jimenez-Muro, Gargallo, & Beamonte, 2012; K. A. Perkins, Donny, & Caggiula, 
1999; Wetter et al., 1999). Women are more likely to report anxiety as a reason for 
relapse to smoking (Xu et al., 2008).  Although globally there is a higher rate of 
smoking for men (40%) than women (approximately 9%) as of 2006 (World Health 
Organization), anxiety disorders have a higher prevalence (23.8%) among females 
than male (15.6%) smokers (Kessler, 2005). There is also a growing incidence of 
anxiety disorders among children and young adults (Kessler, 2005, SAMHSA 2010).  
Initiation of smoking is on the rise in young girls (CDC, 2010; Nichter, Nichter, 
Vuckovic, Quintero, & Ritenbaugh, 1997) but it is not clear if anxiety is a major factor 
contributing to smoking during adolescence.  
Tobacco related mortalities have increased equally amongst men and women 
and although men tend to smoke more than women, women have been found to 
have greater physical and emotional dependence on smoking as measured by 
increased relapse rate due to pre- and post-cessation stressors (Bjornson et al., 
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1995; K. A. Perkins, Donny, & Caggiula, 1999; Xu et al., 2008). Research has shown 
that female smokers also have higher relapse rate and fewer attempts to quit 
smoking compared to male smokers (Bjornson et al., 1995; Wetter et al., 1999). 
Similarly to human studies, in rodent models females also show greater vulnerability 
to nicotine use compared to males has shown by acquisition of self-administration of 
lower doses of nicotine, a reduction in latencies to earn their first infusions of nicotine 
and an enhancement of the rewarding effects in nicotine placed preference in adult 
females compared to male (E. C. Donny et al., 2000; Torres, Natividad, Tejeda, Van 
Weelden, & O'Dell, 2009). Not surprisingly, women are more likely to suffer from 
depression and anxiety disorders (Castle, Kulkarni, & Abel, 2006; Gater et al., 1998) 
and women have also greater tendency than men to smoke in order to relieve 
anxiety as measured by higher relapse rate and smoking more cigarettes (Marqueta, 
Nerin, Jimenez-Muro, Gargallo, & Beamonte, 2012; Wetter et al., 1999). The 
mechanism of how smoking may relieve anxiety is largely unknown.  Using a 
combination of genetic and pharmacological manipulations these studies will assess 
the contributions of β2*nAChRs, α4β2*nAChRs and α6β2*nAChRs to anxiety-like 
behavior in mice.  
 
Anxiety in Humans 
Anxiety can be defined as a subjective emotional response to a stressor that 
involves a “tense, unsettling anticipation of a threat to a vague event” (Rachman, 
2004). Anxiety is a “negative affect related to fear that is diffuse, objectless, 
unpleasant and persistent” (Rachman, 2004) produced by cognitive processes 
mediating the anticipation, interpretation or recollection of perceived stressors and 
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threats (Charney DS and Drevets WC, 2002). During an anxious episode the sufferer 
often has difficulty in the identification of the cause of the uneasy tension or the 
nature of the anticipated threat. These emotional-behavioral responses can be 
brought about by response to exteroceptive visual, auditory, olfactory or 
somatosensory stimuli or to interoceptive input through the viscera and the 
endocrine and autonomic nervous systems (Charney DS and Drevets WC, 2002).  
This definition implies that anxiety is a subjective experience, involving more 
than just physical stressors. Anxiety is commonly evaluated clinically in humans by 
verbal reports. However, anxiety in humans is also associated with nonverbal 
changes in behavior such as increased heart rate, blood pressure and muscle 
tension and palmar sweating (Caruso, 1990). The use of verbal reports is not 
possible for the assessment of experimental or clinical anxiety-like behavior in 
animals. Research has shown that rodents share the same hormones associated 
with stress in humans. Mice lacking the corticotrophin-releasing hormone gene 
exhibit reduced anxiety-like behavior compared to control (Timpl et al., 1998).  In 
order to evaluate anxiety pre-clinically in rodents, investigators rely on the evaluation 
of behaviors that correlate with physiological stress responses seen in both animals 
in humans as well as behaviors that are responsive to anxiolytic drugs. 
Emotional expression involves a range of behavioral, endocrine and 
autonomic manifestations of the emotional response (Charney & Drevets, 2002; 
Fellous, 1999) that is often relayed as a subjective feeling that accompanies the 
response. Emotional processes are modulated by complex neurobiological systems 
that modulate behavior. Anxiety disorders develop when the aspects of emotional 
processing modulated by complex neurobiological systems are maladaptive and 
symptoms become persistent (lasting at least 6 months). 
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Anxiety disorders commonly occur along with other mental and physical 
disorders that may mask or make anxiety symptoms worse. Anxiety disorders 
encompass different disorders including panic disorder, post-traumatic stress 
disorder (PTSD), obsessive-compulsive disorder (OCD), social phobia and 
generalized anxiety disorder (GAD). Each anxiety disorder listed above has different 
symptoms, but all the symptoms involve excessive, often irrational fear and dread.  
Panic disorder is characterized by sudden attacks of terror, usually 
accompanied by changes in the autonomic nervous system such as pounding heart, 
sweatiness and weakness. Panic attacks are usually associated with a fear of 
impending doom or a fear of losing control. Panic disorder affects approximately 6 
million American adults (Kessler RC, Chiu WT, Demler O, Walters EE., 2005) and is 
twice as common in women as men (Kessler RC, Berglund PA, Demler O, Jin R, 
Walters EE., 2005). Panic attacks often begin in late adolescence or early adulthood 
(Kessler RC, Berglund PA, Demler O, Jin R, Walters EE., 2005).  
PTSD typically develops after a terrifying incident that involved physical harm 
or the threat of physical harm. Sufferers of PTSD repeatedly relive the trauma in their 
thoughts during the day and in nightmares when they sleep. This can result in the 
patient losing touch with reality and believing that the traumatic incident is happening 
all over again. PTSD affects roughly 7.7 million Americans and women are more 
likely to develop PTSD than men; PTSD can develop at any age but is most common 
in adulthood (Kessler RC, Berglund PA, Demler O, Jin R, Walters EE., 2005).  
 People with OCD have persistent, obsessions and use rituals (e.g. excessive 
washing or checking) to control the anxiety these thoughts produce. These rituals 
may result in debilitating consequences that affect the patient’s quality of life. OCD 
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affects about 2.2 million American adults and it affects men and women equally; 
OCD usually appears in childhood, adolescence, or early adulthood.  
Social phobia occurs when a person becomes overwhelmingly anxious and 
excessively self-conscious in normal social situations. Social phobia affects about 15 
million American adults and is more prevalent in women than men; this disorder 
usually develops in childhood or early adolescence.  
 People with GAD are characterized as having hyperbolic tension and worry. GAD 
affects approximately about 6.8 million American adults and is twice more prevalent 
in women than men (Robins & Regier, 1991); GAD develops gradually and take 
effect at any time, however, the highest risk occur between childhood and middle 
age. Anxiety disorders affect a large number of the American population, it is 
therefore important to elucidate the mechanisms involved in anxiety disorders to 
better develop effective therapeutics for these often time debilitating disorders.  
Clinical human studies of anxiety disorders include randomized placebo-
controlled double-blind trials of novel pharmacotherapies, imaging methodologies 
and gene expression with pharmacotherapy studies in order to better develop new 
treatment targets, and in order to help personalize future treatment strategies. The 
benefit of human studies of anxiety disorder is that there is better assessment of the 
subjective effects and investigators can better assess the effectiveness of treatment. 
One major setback to studies in humans is that the disorder cannot be easily studied 
mechanistically. Imaging studies in and of themselves can create anxiety 
confounding experimental outcomes and human tissues is often compromised in 
post-mortem studies and are confounded by therapeutic history in treatment of 
anxiety disorders.   
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Sex Hormones and Anxiety 
Women of reproductive age are more prone to developing major depressive 
and anxiety disorders than men, the prevalence being at least two times higher in 
women (Kessler, McGonagle, Swartz, Blazer, & Nelson, 1993; Kessler, Sonnega, 
Bromet, Hughes, & Nelson, 1995; Weissman & Olfson, 1995). Gender differences 
typically emerge during puberty (Bouma, Ormel, Verhulst, & Oldehinkel, 2008) and 
afterwards the prevalence rate in women remains higher until menopause (Kessler, 
2003). The different phases in the reproductive life of women and/or female 
hormonal fluctuations appear to play a role in the gender differences observed. 
Studies have attributed the gender differences in lifetime prevalence rate of affective 
disorders such as anxiety to the cyclic release of female sex hormones particularly 
estrogen (Desai & Jann, 2000; Steiner, Dunn, & Born, 2003).  Typically models for 
anxiety-like behavior are conducted in males. A major reason for using male mice is 
that the cyclic release of female sex hormones, estrogen and progesterone, in 
female mice produces a further and unstable endogenous factor in the models that 
by itself can have significant outcome on physiology and behavior of the animal. 
Since these studies will be performed in females whose gonads are intact, this may 
introduce variability in our dataset that will require increasing our n sizes. Although it 
is important to assess the contributions of sex hormones on anxiety, studies have 
shown that vaginal mechanical stimulation of the internal and external genital 
structures in spontaneous ovulators (e.g. rats, humans, mice, and cattle) induces 
estrus and prolongs and intensifies the immobile mating stance (lordosis) in female 
rats. Studies have shown that common methods of taking vaginal smears in female 
rodents often lead to estrus in animals in which true estrus cannot occur and the 
procedure itself disturbs the regularity of the cycle (Emery & Bchwabe, 1936; Emery 
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& Schwabe, 1938; P. V. Rogers & Allen, 1937; Wade & Doisy, 1935). Extraction of 
serum from the blood is another method for assessing sex hormone levels in rodents 
butprevious studies have shown that it is extremely difficult to accurately measure 
hormone levels in mice (Frick, Fernandez, & Bulinski, 2002)due to the appreciable 
amount of blood needed for these measurements.  The present studies are 
performed only in females. Detection of dichotomies between male and female 
anxiety-like behavior in future studies could be followed-up with experiments that use 
gonadectomy and hormone replacement to determine if sex hormones are driving 
the behaviors observed in rodent studies (Russo et al., 2003).  
 
Anxiety-like Behavior in Rodents 
Humans and mice share a close genetic and physiological relationship where 
the human and the mouse genome share 85% identity. These genomes share 
similar susceptibility to many simple and complex genetic diseases.  Intensive 
inbreeding has provided many genetically isogenic strains with phenotypically 
distinct features that have been successfully used to identify and often define the 
genetics of many models of human disease. Different mouse strains provide a 
resource for examining the genetic diseases including those that include drugs of 
abuse. However, caution is needed when embarking upon experiments using the 
mouse model systems. An important factor to consider is that alteration or deletion of 
a gene leads to compensatory mechanisms that are present over the lifetime of the 
animal. This makes it difficult to determine whether the effects observed in 
genetically modified mice are due the alteration of a gene, or if they are due to 
compensatory changes that occur during development. Therefore, each experiment 
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and finding must be evaluated as to species-specific responses to stressors, 
suitability of experimental manipulations, equipment and assessment strategy and 
strain and species limitations in behavioral and adaptive repertoires.  
Preclinical studies using animal models that model human pathological 
anxiety in rodents are a useful way of mechanistically identifying potential molecular 
targets for treatment of anxiety. Animal models shown to respond to drugs that are 
anxiolytic in humans are believed to have some predictive validity for therapeutic 
efficacy and may identify new therapeutic targets for treatment of anxiety. Non-
human animals possess the same neurotransmitters and brain areas that regulate 
anxiety. Animal studies can control for behavioral and environmental factors that are 
difficult to control in humans.  In these studies we will use mice. Mouse models 
benefit from transgenic approaches that can be used to study molecular 
contributions to anxiety-like behavior (for review on see (Cryan & Holmes, 2005).  
 Preclinical animal models use non-verbal behavioral tests for the assessment of 
anxiety-like behavior that include: exploration-based conflict tasks and non-
exploration based tests.  Most ethological procedures in anxiety models are 
designed to trigger relevant ethological conflict/conditioned behaviors. Exploration-
based conflict tasks are the most commonly used anxiety-like tests in rodents. 
Rodents such as mice have an innate aversion to open and brightly lit spaces. 
Conversely, mice will naturally explore new environments. Exploration-based conflict 
tasks take advantage of the competing ethological drives of mice to avoid predation 
and to explore a novel environment.  Exploration-based conflict tasks such as the 
elevated plus maze, the mirror task, the open field, and the light-dark task utilize 
test apparatuses where the mouse’s drive to approach is in disagreement with the 
avoidance of the potential threat. These tests are sensitive to locomotor effects of 
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drugs, so that locomotor activity should be assessed for potential confounding 
effects in these tasks.  
Conversely, non-exploration based tests, e.g. conditioned inhibition, 
marble burying and acoustic startle response do not rely on exploration and 
hence allow the measurement of anxiety-like behavior where it is less difficult to 
separate changes in locomotor activity from anxiety-induced changes in activity.  As 
with the conflict tasks, drugs with anxiolytic action in humans produce decreases in 
avoidance of aversive or threatening areas in (non- mutant) mouse strains and 
anxiogenic drugs have been shown to have the opposite effect (K. R. Bailey & 
Crawley, 2009; Holmes, 2003).   
Various methodical procedures are employed when designing experiments. 
These procedures include the environmental condition in which the animals are 
housed (this should be kept consistent across experiments), food and water access 
should be ad libitum, experimental history of subject, prior test and drug exposure 
and housing.   
The aversive or threatening area in animal models of anxiety can take various 
forms; an open, elevated arm (elevated plus maze), open, elevated quadrant 
(elevated zero maze), light compartment or arena (light- dark exploration test, 
emergence test), mirrored arena (mirrored chamber test), a staircase (staircase 
test), an area in which a predator was previously encountered (mouse defense test 
battery, predator exposure test), or central area of a novel or brightly lit open fields 
(open-field test). 
Studies have shown that drugs known to alleviate anxiety in humans produce 
reduced anxiety-like behavior in animal models (Calabrese, 2008; Turner, 
Castellano, & Blendy, 2010; Turner, Castellano, & Blendy, 2011). The open-field 
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(OF) test allows for the assessment of novel exploration and general locomotor 
activity. Two factors have been shown to influence anxiety-like behavior in the OF 
test, these are social isolation and stress created by brightly lit, uncovered, novel 
environment. Subjects are placed in an open area and dependent measures are 
analyzed such as time spent in the center of the arena. Experiments are usually 
conducted in brightly lit conditions. 
 Increased digging behavior in rodents is associated with physiological stress 
responses and is decreased by treatment with anxiolytics (Njunge & Handley, 1991). 
The marble-burying test is a paradigm used to assess drugs used to treat anxiety 
in humans. This ethological test assesses non-exploratory behavior and consists of a 
cage filled with loose bedding and identical glass marbles placed at equidistance 
from each other. Previous work has shown that benzodiazepines known to relieve 
anxiety in humans reduce the number of marbles buried in rodents (Nicolas, Kolb, & 
Prinssen, 2006; Njunge & Handley, 1991). A reduction in the number of marbles 
buried is interpreted as reduced anxiety-like behavior in rodents.   
The light-dark exploration test (LD) assesses the ethological drive of 
rodents to avoid predation by hiding in an enclosed dark chamber and to explore 
their environment. The apparatus for the LD test typically consists of a small dark 
enclosed chamber and a larger, open, brightly lit chamber. Rodents find lighted open 
areas aversive and this inhibits the ethological drive in rodents to explore a novel 
environment. An increase in exploratory activity is interpreted as a release of 
exploratory inhibition and is thus interpreted as decreased anxiety-like behavior. 
Dependent variables include total locomotor activity counts in both chambers and 
time spent in the light chamber. When animals start in the dark chamber, latency to 
enter the light chamber can also provide a measure of anxiety-like behavior. 
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Typically an enhancement of exploratory behavior should not be due to general 
increases in locomotor activity (Bourin & Hascoet, 2003). Overall changes in 
locomotor activity can be assessed by comparing activity in the light and dark 
chambers.   
 Previous work has shown that the LD assay, MB test and OF tests are valuable 
tools in the assessment of the anxiety-phenotype (Bourin & Hascoet, 2003; J. Cao et 
al., 2010; Nicolas, Kolb, & Prinssen, 2006; Njunge & Handley, 1991).  
The elevated plus- maze or elevated zero- maze (EPM/EZM) takes 
advantage of the natural tendency of mice to explore novel environments. The EPM 
was originally designed in 1985 as a screening tool for the assessment of anxiolytic 
and anxiogenic drugs on exploratory activity in rodents. As stated above this test 
takes advantage of the approach-avoidance conflict behavior that is associated with 
an increase in physiological stress indicators. The apparatus EPM consists of 2 
opposite closed arms (alleys with walls) and 2 perpendicular and opposite open 
arms (alleys with no walls). Like the open field, EPM experiments are also conducted 
in brightly lit conditions. Animals are allowed to freely explore the different arms with 
the open arms being presumably more aversive since mice spend much less time 
there. Anxiolytic drugs help to reduce the inhibition of open arm exploration 
(Calabrese, 2008).  Typical dependent variables include the number of open and 
closed arm entries and time spent in open and closed arms. An advantage of using 
this model is that, unlike LD and OF, behavior is consistent over multiple days and 
hence can be utilized over several days of training.  
An advantage of using ethological tests such as EPM, LD, OF and MB is that 
no prior training is needed and animals do not need to food or water deprived. Other 
animal models of anxiety that require prior training include the fear conditioning, 
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conditioned emotional response (CER), fear potentiated acoustic startle, and 
the place conditioning paradigms. These models must include behavioral controls 
to assess if changes in anxiety-like behavior are learning-dependent. 
Fear conditioning, potentiated acoustic startle and conditioned 
emotional response involve a learned emotional anxiety or fear reaction to in 
response to predictive cues associated with an aversive stimulus. These Pavlovian 
measures involve the presentation of a conditioned stimulus (CS) (e.g. light and 
tone) with an unconditional stimulus (US) (e.g. foot shock). After several pairings, the 
US comes to elicit the unconditional response (UCR).  In fear conditioning and CER 
the CS evokes freezing and a suppression of lever-pressing respectively. With CER, 
the disruptive effect of the CS on goal-oriented behavior is termed conditioned 
suppression. Conditioned suppression is the amount of suppression of on-going 
operant behavior and is used as an indicator of the strength of fear.  In contrast, an 
aversive CS. CER enhances acoustic startle reflexes and acoustic startle responses 
are reversed by drugs that are used to treat anxiety disorders in humans such as 
benzodiazepines (chlordiazepoxide, diazepam and oxazepam) (for review see 
(Davis, 1990). 
During place conditioning or conditioned avoidance a stimulus such as a 
drug or a foot shock is paired with an environment that the animal can voluntarily 
choose to spend time in during a test. Dependent measures are latency to enter or 
leave the conditioned chamber and time spent in the chamber where animals 
received a shock. Place conditioning is a useful behavioral model to study the 
rewarding and aversive effects of a drug. The apparatus commonly consisting of a 
three-compartment chamber designed to have different characteristics. The center 
compartment has no discernible characteristics and is not paired with a drug. The 
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gates between the compartments can be left opened to allow an animal to pass 
freely between them. During training an animal is given an injection with a drug and 
consistently placed in a paired compartment for several minutes. Control injections 
are followed by placement in the other compartment. Training typically involves 3-4 
sessions for each drug and vehicle. On test day, the animal is allowed to move freely 
between compartments. Dependent measures include the time spent in the drug-
paired compartment. Decreases and increases from baseline determine if the drug 
was respectively aversive or rewarding during training (Brunzell, Mineur, Neve, & 
Picciotto, 2009; Prus, James, & Rosecrans, 2009). This thesis work utilizes a 
number of behavioral tasks to assess anxiety-like behavior in mice; these include the 
OF, MB and the LD. 
 
Physiology and Anatomy of Anxiety 
The physiology of emotional states relating to anxiety disorders is found in the 
lower regions of the brain. These regions include the limbic system, diencephalon, 
the reticular formation and its connecting brain circuitry. The neuroanatomical circuits 
associated with anxiety are modulated by a variety of chemical neurotransmitter 
systems. These include neurotransmitters whose release is modulated by nAChRs: 
norepinephrine (NE), serotonin (5-hydroxy-tryptamine, 5-HT), dopamine (DA), and γ-
aminobutyric acid (GABA) (J. P. Changeux et al., 1998; M. R. Picciotto, Brunzell, & 
Caldarone, 2002). Nicotine also regulates peptidergic neurotransmitters and 
hormones, corticotropin releasing hormone (CRH), neuropeptide Y (NPY) substance 
P, adenosine, and cytokines, suggesting a role for nAChRs in their modulation 
(Millan, 2003). The best-studied neurotransmitter systems connected with anxiety 
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involve stress hormones of the hypothalamic-pituitary-adrenal (HPA) axis and the 
central noradrenergic system. These neurochemical systems are important for 
adaptive functions in preparing the organism for responding to the stressor by the 
modulation of various survival mechanisms. When dysfunction occurs, these 
biological responses to threat or stress may become maladaptive if they are 
chronically or inappropriately activated.  
Disruption of the serotonergic, noradrenergic, dopaminergic and/or 
GABAergic pathways has been implicated in supporting anxiety disorders. 
Ascending serotonergic projections originates from cell bodies located along the 
midline of the brain stem, in the raphe nuclei in pons and midbrain that project to 
forebrain. This pathway plays an important role in the regulation of responsiveness 
of cortical neurons involved in mood. Projections from the raphe nuclei project to 
brain regions such as the prefrontal cortex and forebrain. Studies have shown that 
elevated raphe nucleus 5-HT 1B levels are associated with reduced anxiety in rats 
exposed to stress as shown by increased entries in the open arms of the elevated 
plus maze (Kaiyala, Vincow, Sexton, & Neumaier, 2003). Exposure to various 
stressors results in increased 5-HT metabolism in the medial pre-frontal cortex 
(mPFC), amygdala, lateral hypothalamus and nucleus accumbens in rat brains 
(Inoue, Tsuchiya, & Koyama, 1994). 
Ascending noradrenergic projections originate from cell bodies located in the 
dorsal and ventral medulla. NE-containing neurons located in the locus coeruleus 
(LC) provide important projections to the cerebral cortex and cerebellum and are 
important for maintaining responsiveness to unexpected stressors. Projections from 
the LC that extend to the limbic system regulate anxiety (Cheeta, Irvine, Kenny, & 
File, 2001; J. M. Weiss et al., 1994). Drugs used to treat anxiety in humans such as 
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benzodiazepines.have been found to inhibit LC activity in rodents (Kozak, Valzelli, & 
Garattini, 1984), which is thought to support the anxiolytic effects of these drugs.  
However, some studies have found that local LC infusion of drugs that decrease 
neuron firing resulted in anxiogenic behavioral responses (J. M. Weiss et al., 1994). 
Conversely drugs used to increase the firing of cells in the LC resulted in anxiolytic 
responses (J. M. Weiss et al., 1994). The mesolimbic system is one of the major DA 
pathways in the CNS. Ascending dopaminergic projections originate in the ventral 
tegmental area (VTA) and the substantia nigra (SN). Dopaminergic neurons in the 
ventral tegmentum (mesocortical pathway) project to the frontal lobes where they 
contribute to the emotional response to anxiety. Studies in which a mutant strain of 
mice for the Clock gene Δ19, which has a complete behavior profile similar to human 
mania when injected with an inwardly rectifying potassium channel subunit (Kir2.1) 
into the VTA, which mimics the effects of the treatment for mania with lithium, mutant 
mice showed anxiogenic behavior compared to control mutant mice virally 
transfected with green florescent protein (Coque et al., 2011). Nicotine mediates 
reward and aversive motivational effects in humans and animals. The VTA is 
believed to play a crucial role in mediating the rewarding and aversive properties of 
nicotine. Laviolette and van der Kooy (2003) have shown that that blockade of 
mesolimbic DA transmission blocks nicotine aversion and increases the sensitivity to 
the rewarding effects of nicotine following local administration into the VTA 
(Laviolette & van der Kooy, 2003). This suggests that VTA DA signals may be 
anxiogenic and further highlights the importance of the mesocortical pathway in 
anxiety. The mesolimbic pathway extends from the VTA of the midbrain to areas of 
the limbic system. The limbic system includes the nucleus accumbens, amygdala 
and hippocampus and is associated with reward and pleasure as well as 
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motivational valence for aversive behaviors. The limbic system, mesocortical 
pathway and the nigrostriatal pathway are involved in the inhibitory function of 
dopaminergic neurons. Acute stress leads to an increase in DA release from nerve 
terminals and metabolism in many brain regions. Research has shown that the 
mesolimbic dopamine system plays an important role in anxiety behaviors (Barrot et 
al., 2001; Barrot et al., 2002; Barrot et al., 2005; Olson et al., 2005).  GABA is the 
major inhibitory neurotransmitter in the CNS and is found in nearly every region of 
the brain. GABA receptor function can be altered by exposure to stress and 
activation of this pathway leads to decreased anxiety. Central GABAA receptors are 
expressed throughout the brain, but are most densely concentrated in the cortical 
gray matter. Central GABAA receptors agonists potentiate and prolong the synaptic 
actions of the inhibitory neurotransmitter, GABA, by increasing the frequency of 
GABA-mediated chloride channel openings (D. W. Choi, Farb, & Fischbach, 1981; 
Millan, 2003).  
 Taken together, these neural networks provide a various mechanisms by which a 
stressor can influence behavior and mood.  
 
Treatment for Anxiety Disorders 
Typically, anxiety disorders are treated with medications, psychotherapy or a 
combination of the two. Psychotherapy such as cognitive-behavioral therapy is a 
useful tool for treating anxiety disorders (Otte, 2011). An anxiogenic agent is one 
that causes an increase in anxiety. In comparison anxiolytic agents are those that 
reduce or relieve anxiety. Typically, treatment with anxiolytics act by inhibiting 
neuronal activity in brain structures that mediate fear expression and the behavioral 
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sensitization and facilitation of endogenous mechanisms necessary for the 
modulation of the neural transmission of information about aversive stimuli and 
responses to such stimuli. Anxiety disorders are principally managed with 
medications (Koen & Stein, 2011) that include, selective 5-HT reuptake inhibitors 
(SSRIs) antidepressants such as fluoxetine (Prozac), serotonin (5-HT)1A receptor 
agonists, tricyclics such as imipramine (Tofranil), monoamine oxidase inhibitors 
(MAOIs) such as phenelzine (Nardil), beta-blockers such as propranolol (Inderal) 
and drugs  that enhance GABA receptor activity such as benzodiazepines (BDZs) 
and buspirone. 
Given self-reports suggesting that cigarettes and smokeless tobacco relieve 
anxiety; it is possible that nAChRs may promote anxiolysis. nAChRs are ubiquitously 
expressed throughout the brain including limbic structures such as the amygdala, 
prefrontal cortex, hippocampus and sensory thalamus that regulate anxiety (J. P. 
Changeux et al., 1998; M. R. Picciotto, Brunzell, & Caldarone, 2002). The nAChRs 
reside predominantly on neuronal soma and axon terminals where they modulate the 
release of GABA, DA, NE and 5-HT in response to stimulation by nicotine or the 
endogenous neurotransmitter ACh (J. P. Changeux et al., 1998).  
 
Age differences and Anxiety 
Along with sex difference, the prevalence of anxiety is also age-dependent.  
Young adults with nicotine dependence had higher rates of major depression and 
anxiety disorders (Breslau, Kilbey, & Andreski, 1991). The properties of the nAChRs 
on dopamine terminals change with age (Alves, Bailey, Nashmi, & Lambe, 2010) and 
during early development there is a large distribution of α4β2*nAChRs in the cortex 
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and changes in the expression of α4β2*nAChRs differentially affects anxiety-like 
behavior in young and aged mice. Studies in mice report that aged (24 to 28-month-
old) mice have reduced expression of α4β2*nAChRs compared to young (4 to 6-
month-old) mice (S. W. Rogers, Gahring, Collins, & Marks, 1998). Similarly, human 
imaging studies the elderly have shown a decrease in nAChR availability as we age 
(Mitsis et al., 2007; Mitsis et al., 2009). In males, aged rats shown increased anxiety 
compared to younger rats (Meyza, Boguszewski, Nikolaev, & Zagrodzka, 2011; 
Pietrelli, Lopez-Costa, Goni, Brusco, & Basso, 2012). Taken together, these results 
show the importance of investigating the role nicotinic receptors play in age-
dependent changes in anxiety.  This thesis will compare anxiety-like behavior across 
the life span in 6, 12 and 24-month-old female wild type, α4nAChR subunit knockout 
(α4KO) mice and α4nAChR heterozygous (α4HET) mice.  
 
Experimental procedures 
In these experiments to assess the contributions of the β2*nAChRs to anxiety-
like behavior in female mice a number of mouse models of anxiety-like behavior was 
used. Behavior was initially assessed in the light-dark assay, followed by the marble 
burying test and the open field test of the locomotor activity assay.  
To assess the contribution of β2*nAChRs to anxiety-like behavior in middle 
aged and aged females, 12- and 24-month-old mutant mice with a null mutation 
(β2KO) of their β2 subunits and heterozygous (β2HET) animals with a 50% reduction 
of their β2*nAChRs were compared to wild type controls (WT) in a light-dark assay, 
marble burying task and open field test. To pharmacologically assess if activation or 
inhibition of β2*nAChRs promotes anxiety-like behavior; mice were injected with 0 or 
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2.3 mg/kg i.p., DHβE prior to testing in the light-dark and marble burying task. To 
further assess the stoichiometry of β2*nAChRs that contribute to anxiety-like 
behaviors across the lifespan, 6-, 12-, and 24-month old female mice with a null 
mutation of their α4 subunits (α4KO), α4 nAChR subunit heterozygous (α4HET) and 
wild type control mice (WT) were also studied in a light-dark assay and marble 
burying task following injection of saline vehicle or 2.3 mg/kg i.p. DHβE. As with 
β2*nAChR mutant mouse studies, α4 mice were assessed in the open field in the 
absence of drug injection. β2*nAChRs also assemble with the α6 subunit both in the 
presence or absence of α4. To assess the role of the α6β2*nAChRs to anxiety-like 
behavior, adult, female mice with a single point mutation in their α6 subunit which 
renders them hypersensitive to nicotine (α6L9S) were compared to their wild type 
(WT) littermate controls in the light-dark assay and marble burying task. Mice were 
injected with 0, 0.001, 0.0032, 0.01, 0.032, 0.1 and 0.32 mg/kg i.p., (freebase) 
nicotine prior to anxiety assays as well as prior to a locomotor task.   
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Materials and Methods 
 
Animals 
Female wild type, knockout, or transgenic mice on a C57BL6J background 
were bred in a vivarium at VCU for all experiments and were housed in cages of 
groups of 3-6. Mice were separated into 3 groups by age with 6-month-old animals 
representing adult mice, 12-month-old mice considered middle aged and 24-month-
old mice representing the aged group for these experiments. β2 (β2KO) and α4 
(α4KO) subunit null mutant mice were generated from heterozygous matings 
backcrossed at least 14 generations onto a C57BL6J background. Heterozygous 
mice that have a 50% reduction in their respective β2* (β2HET) and α4*nAChRs 
(α4HET) were also studied and wild type mice served as controls. α6 subunit 
bacterial artificial chromosome transgenic gain of function mice with one allele 
containing a single point mutation of serine to leucine in the pore-forming region of 
the M2 domaine (α6 L9S) were crossed to C57BL6 mice (Drenan et al., 2008).  Ear 
punches were used to identify animals and confirm genotype using PCR analysis. 
Mice were housed 3-5 per cage and maintained in a temperature- and humidity -
controlled vivarium (20-22 °C) under a 12: 12 h light-dark cycle (lights on at 06:00 
hours). Food and water were available ad libitum. Mice were habituated to handling 
at least 3 days before behavioral testing. Behavioral tests were conducted between 
0800 and 1700 hours. All studies were approved by the Virginia Commonwealth 
University Animal Care and Use Committee and followed National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.  
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Drug Dosing and Administration 
Mice undergoing behavioral testing received intraperitoneal (i.p.) injections of 
di-hydrobeta-erythroidine (DHβE) (Tocris Bioscience; Bristol, U.K.) or nicotine 
hydrogen tartrate (Sigma Aldrich; St. Louis, MO, U.S.A). DHβE in 0.9% sterile saline 
was administered at 0 or 2.3 mg/kg (freebase) 15 minutes prior to behavioral testing 
and placed in a novel holding cage. The following nicotine doses in 0.9% sterile 
saline were administered to subjects immediately prior to testing: 0, 0.001, 0.0032, 
0.01, 0.032, 0.1 and 0.32mg/kg (nicotine doses are expressed as freebase).  
 
Apparatus 
Light-dark Assay 
Light-dark experiments were conducted in modified Med Associates place 
conditioning chambers (St. Albans, VT, U.S.A.).  The dimensions of the chambers 
were: light (L 26.5 cm x W 12.7 cm x H 26.2 cm) and dark (L 16.8 cm x W 12.7 cm x 
H 12.7 cm), with the light chamber being open (no ceiling) and illuminated with a 
single 23W n: vision fluorescent LED light bulb. The adjacent dark chamber was 
enclosed with a dark lid and the experimental room was unlit except for the 
illumination provided by the light chamber.  There was a (10.3 cm x 5.3 cm) door that 
enabled movement between chambers. Data was collected on a PC computer using 
Med Associates software.     
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Marble Burying Test 
Marble burying experiments were conducted in standard mouse polycarbonate 
cages (30 cm L x 18 cm W x 18.5 cm H) filled with 5 cm of loose sawdust bedding. 
The outer perimeter of the cages covered by white card-stock to occlude 
visualization of other mice. Cages were covered with a transparent Plexiglas lid with 
3 (0.9 cm in diameter) holes drilled in the center. 20 glass marbles of the same size 
and color were placed atop the sawdust in a 4 x 5 grid in the cage with a 1-inch 
perimeter between the marbles and the walls of the polycarbonate cage.  
 
Open-field Test 
The open-field experiments were conducted in a translucent, square experimental 
chamber (42 cm L X 42 cm W X 30 cm H; Med Associates ENV-515). On the 
exterior of the chamber, a strip of 16 X 16 infrared photocell beams placed 1 inch 
apart and 2.5 inches from the floor detected horizontal movement via beam breaks. 
The chamber was calibrated to enable measurement of distance traveled and center 
activity. A second row of 16 x 16 photosensors placed 4.5 inches from the floor 
tracked vertical movement of the mice. The photocells were interfaced to a PC 
computer running MedPC software for recording and analysis. Experiments were 
conducted under dim lighting conditions.  
 
Locomotor Activity 
The locomotor activity experiment was conducted in a modified standard 
mouse chamber (L 30 cm x W 18 cm x H 18.5 cm) with the ventilation nozzle 
removed and a white card fixed over the area. Mouse chambers were placed inside 
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a white Plexiglas framebox measuring 33 cm x 20 cm x 19 cm made from white card 
and interfaced with a PC running ANY-maze software for recording and analysis of 
locomotor and rearing activity.  
 
Behavioral Procedures 
Prior to all experiments mice were handled to acclimate to experimenter and 
experimental procedures. 
 
Light-Dark Assay 
The day prior to testing animals were acclimatized to the test room, weighed 
and tails were marked to facilitate identification by the experimenter. On test days, 
the experimental room was dark apart from the lighting required for the light-dark 
experiment. Mice weighed and acclimated to the lighting conditions for at least 1 
hour prior to testing. The apparatus and dropping trays were thoroughly cleaned with 
70% Novasan before each trial. Animals were administered i.p. injections of vehicle 
(0.9% sterile saline) or drug (DHβE or nicotine) and were placed into the dark 
chamber, with the lid closed. Dependent variables included latency to enter the light 
chamber, defined as the time elapsed from the beginning of the experiment until the 
first entry was made in the light chamber, movements per second in each chamber 
with a locomotor movement unit defined as the two adjacent beam breaks (distance 
of 3 cm between light beams), entry into a chamber was defined as the subject 
breaking the second beam in the adjacent chamber (distance of 4.5 cm) and 
exploration of a chamber was defined as the subject breaking the first beam in the 
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adjacent chamber (distance of 1.5 cm). All data was broken down into 10 one-minute 
time bins.  Behavior was assessed for ten minutes. 
Dependent variables of latency, total movement and percentage of time spent 
in the light chamber were analyzed using a 3 way (genotype x age x test drug), 
between-subject ANOVA. Movements per second were analyzed using a repeated 
measure within-subject ANOVA with genotype and test drug as between-subject 
factors. Significant effects of time-bin were followed up by analysis using a further 
breakdown of the data. Tukey HSD post hoc tests evaluated main effects of DHβE 
studies and LSD tests were used for post hoc analysis of the nicotine dose-response 
curves. Two-tailed post hoc t-tests were carried out where appropriate to assess 
significant interactions. The criterion for significance was set at p < 0.05. 
 
Marble burying test 
Animals were habituated to the test room for at least 3 days prior to testing. 
Mice were weighed and had their tails marked with non-toxic indelible marker to 
expedite mouse identification during testing. On test day, animals were acclimated to 
the test room 2 to 3 hours prior to experimentation. All mice were weighed and 
returned to home cages. Animals were administered vehicle (saline) or drug (DHβE 
or nicotine) i.p., and placed in a holding cage for 15 minutes. For testing, subjects 
were placed at the perimeter of the marble grid inside of marble burying apparatus. 
Mice were allowed to dig and explore the apparatus for the duration of the 
experimental session.  For subjects administered DHβE behavior was assessed for 
30 minutes. For subjects administered nicotine behavior was for 15 minutes.  
Marbles at least ½ covered were defined as buried. A genotype x age x treatment, 
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between-subjects ANOVA was used to assess marbles buried. Tukey HSD post hoc 
tests evaluated main effects with more than one level for DHβE studies and LSD 
tests evaluated significant effects for the nicotine dose response curves. Two-tailed 
Post hoc t-tests were carried out where appropriate to assess significant interactions. 
Criterion for significance was set at p < 0.05. 
 
Open-field test 
On test days, animals were acclimated to a holding room adjacent to the test 
room for at least 30 minutes prior to testing.  Animals were then transferred as a 
group in home cages to the test room at the time of testing. The open field apparatus 
was cleared of any debris and thoroughly cleaned with 70% ethanol before each 
trial. Unlike the marble-burying test and open-field, no drug was given during the 
open-field test. Mice were placed in the central-most quadrant of the illuminated 
open-field arena and allowed to freely explore the apparatus for a period of 10 
minutes. Dependent variables of time spent in the center, time spent in the periphery 
(thigmotaxis), distance travelled in the center and vertical counts in the center were 
analyzed using a between-subjects ANOVA to assess differences between 
genotypes and age. The criterion for significance was set at p < 0.05.  
 
Locomotor activity 
The day prior to test day animals were acclimatized to the experimental room, 
weighed and tails were marked with non-toxic indelible ink. On test days, the 
experimental room was dimly lit by two 23W n: vision fluorescent LED light bulb 
placed at 11 inches from the chambers.  All animals were weighed and returned to 
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home cage and acclimated to the room for a period of 1 to 2 hours prior to testing. 
The locomotor apparatus was cleared of all debris and thoroughly cleaned with 70% 
Novasan before each trial. Animals were administered vehicle (saline) or drug 
(nicotine) i.p. and were placed into the apparatus for 10 minutes. Distance travelled, 
time immobile, wall rearing and time spent rearing were measured. A between-
subject (2 x 7; genotype x nicotine treatment) ANOVA was used to assess 
significance of behavioral parameters, and the criterion for significance was set at p 
< 0.05. Post hoc LSD tests assessed significance between groups following main 
effects and two-tailed Post hoc t-tests were carried out where appropriate to assess 
significant interactions of drug treatment within a genotype.  
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Results 
 
Assessing the contributions of the β2*nAChRs on anxiety-like behavior 
To assess contributions of high affinity β2*nAChRs to anxiety-like behavior, 
WT, β2HET and β2KO mice were tested in the light-dark, marble burying and open 
field assays.  Prior to light-dark and marble burying assays, mice also received 
injection of saline vehicle or DHβE, a selective β2*nAChR antagonist.  
Light-Dark Assay 
There was no effect of genotype, age or DHβE treatment on mouse latencies 
to enter the light chamber or on the percentage of time that mice spent in the light 
chamber (Figure 1).  For the measure of movements per second in the light 
chamber, however, there was a nearly significant interaction of genotype x age x 
treatment (F2, 47 = 3.131, p = 0.053).  There was also a significant interaction of time 
bin x genotype x treatment for the measure of movements per second in the light 
chamber (F18, 423  = 2.017, p = 0.008; Figure 2). Subsequent analysis of the first and 
last 5 time bins returned a significant interaction of genotype x age x treatment on 
movements per second in the light chamber during the first 5 min (F2, 47 = 3.220, p = 
0.049), but not during the last 5 min of the 10 min session (Figure 3). These effects 
were apparent in aged (24 month) but not middle aged (12 month) mice. Post hoc t-
tests revealed that saline-injected, 24-month-old β2KO mice showed a trend for 
greater exploration of the light chamber than saline-injected 24-month-old WT mice. 
Following DHβE injection, however, WT and β2KO mice showed a similar level of 
exploration activity as measured by movements per second in the light chamber, 
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suggesting these effects were mediated by β2*nAChRs. It is interesting that a 
reduction of β2*nAChR expression in β2HET mice appeared to result in the opposite 
effect following DHβE treatment in 24-month-old animals. Post-hoc t-tests revealed a 
significant difference between WT and β2HET mice following DHβE injection (p = 
0.03). These effects were specific to the light chamber. There was no effect of 
genotype, age or treatment on movements per second in the dark chamber, 
suggesting that these observations were not due to non-specific effects of genotype, 
age or treatment on locomotor activity but were specific to exploration of the more 
aversive light chamber. Due to small n sizes in some of these groups, these 
preliminary data should be replicated (Table 1). 
 
Marble Burying Task 
  There was a main effect of genotype (F2, 60 = 4.219, p = 0.02) and a non-
significant trend for an interaction of genotype x age (F2, 60 = 2.974, p = 0.06) for 
number of marbles buried (Figure 4). Post hoc t-tests revealed that 12-month-old 
β2HET mice buried significantly fewer marbles than their wild type counterparts (t 13 
= 3.507, p = 0.004), suggesting that a reduction in β2*nAChR expression promoted 
anxiolysis-like behavior in these mice. This was not observed when β2*nAChRs 
were completely absent, however; there was no significant difference in marble 
burying between WT and β2KO mice at 12 months. There were also no differences 
between WT and β2KO or β2HET mice observed at 24 months of age (t’s < 1.0) 
when WT subjects would be expected to show an overall reduction in the expression 
of their β2*nAChRs (S. W. Rogers, Gahring, Collins, & Marks, 1998). 
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Open Field 
  There was a significant effect of genotype on distance traveled in the 
perimeter (F2, 93 = 3.664, p = 0.03) but not in the center of the open field test (Figure 
5). Compared to WT subjects, β2KO mice traveled a greater distance around the 
perimeter of the field (t70 = 1.95, p = 0.055). There was no difference between WT 
and β2HET perimeter activity (t54 = 0.75, p = 0.457). There was also a significant 
effect of genotype on rearing activity as measured by vertical counts in the perimeter 
of the open field. Post hoc t-tests showed that β2KO mice reared more than WT 
mice (t70 = 2.302, p = 0.024). There was no difference observed between WT and 
β2HET mice. There was no effect of genotype on rearing activity in the center of the 
chamber or on total time spent in either the center or the perimeter of the open field 
(F’s < 1.0).  Together these data are consistent with studies, which suggest that 
β2KO mice show elevated levels of exploration (Avale et al., 2008; King, Caldarone, 
& Picciotto, 2004). 
 
Assessing the contributions of the α4*nAChR on anxiety-like behavior  
To assess contributions of high affinity α4*nAChRs to anxiety-like behavior, 
WT, α4HET and α4KO mice were tested in the light-dark, marble burying and open 
field assays.  Prior to light-dark and marble burying assays, mice also received 
injection of saline vehicle or DHβE, a selective β2*nAChR antagonist.  
High affinity β2*nAChRs assemble with the α4 subunit in most areas of the brain. 
Anxiety assays were performed in α4HET and α4KO mice to assess if the α4 
subunit contributes to anxiety-like behavior in the light-dark and marble burying task 
as well as to assess if a loss of function of the α4*nAChRs would open field tasks.   
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Light-Dark  
 There was a main effect of genotype (F2, 74 = 3.341, p = 0.038) and a main 
effect of treatment (F2, 74 = 6.466, p = 0.013) for latency to enter the bright chamber 
(Figure 6). α4KO mice displayed longer latencies to enter the light chamber 
compared to WT mice (p = 0.03), suggesting that absence of this subunit supported 
an anxiogenic-like phenotype. Partial deletion of the α4*nAChRs was not sufficient 
for expression of this phenotype, there was no difference in latency between WT and 
α4HET mice. Similarly, antagonism of β2*nAChRs with DHβE resulted in an 
elevation in latency, suggesting that blockade of α4β2*nAChRs might support 
anxiogenesis in female mice.  There was also a significant effect of genotype (F2, 74 = 
4.311, p = 0.017) and treatment (F1, 74 = 4.009, p = 0.049) for percentage of time 
spent in the light chamber (Figure 7). As with latency measures, α4KO mice but not 
α4HETs spent significantly less time in the light chamber than WT mice (p = 0.008) 
and DHβE injection led to a significant reduction in time spent in the light chamber. 
There was a nearly significant main effect of genotype for movements per second in 
the light chamber (F2, 74 = 3.060, p = 0.053) and a significant main effect of genotype 
on movements per second in the dark chamber (F2, 74 = 4.755, p = 0.011).  Post hoc 
tests indicated that α4KO but not α4HET mice showed a trend for less exploration 
than WT mice in the light chamber (p = 0.09). This was in the opposite direction of 
dark chamber exploration activity where α4KO mice showed a significant elevation in 
movements per second compared to WT mice (p = 0.006). Overall these data 
support previous findings suggesting that α4*nAChRs regulate anxiety-like behavior. 
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Due to small n sizes in some groups, however, these data should be replicated 
(Table 1). 
 
Marble Burying 
 There was a main effect of age (F1, 74  = 9.428, p = 0.003) on marble burying 
behavior indicating that aged mice buried overall significantly fewer marbles than 
middle aged animals (Figure 9). Although main effects for genotype and DHβE 
treatment failed to reach significance, there was a significant interaction of genotype 
and treatment (F2, 74  = 3.414, p = 0.038). DHβE injection led to a significant reduction 
of marbles buried in α4HET mice (p < 0.007) but not in WT mice. It is possible that 
α4HET mice were more responsive to the antagonist due to a reduction in their basal 
level of α4β2*nAChRs or in the shift of the configuration of these receptors to the 
α42β23 stoichiometry.  In contrast, there was no effect of DHβE treatment on marble 
burying in α4KO mice, supporting the hypothesis that this effect was driven by 
receptors that contain α4 and β2 subunits, i.e. α4β2*nAChRs.  Drugs used to treat 
anxiety in humans have been found to reduce the number of marbles buried this task 
(Nicolas, Kolb, & Prinssen, 2006)these results suggest that inhibition of 
α4β2*nAChRs may promote anxiolysis.    
Open Field 
 There was no effect of genotype and no interaction of genotype with age on 
any measure in the open field study. WT, α4HET and α4KO mice spent a similar 
amount of time in the perimeter and the center of the open arena and did not differ in 
their rearing activity in the center or the perimeter of the field (Figure 10). This is in 
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contrast to the observation above that β2KO mice spent significantly more time in 
exploration of the perimeter of the maze, suggesting that a stoichiometry other than 
α4β2*nAChRs, perhaps α6β2*nAChRs, might regulate exploration in an open field. 
There was a significant main effect of age for time spent in the center of the open 
field (F2, 111  = 3.283, p = 0.041), rearing in the center (F2, 111  = 4.240, p = 0.017), and 
rearing in the perimeter (F2, 111  = 17.250, p < 0.001) of the open field.  Post-hoc tests 
revealed that 12-month-old mice spent more time than 24-month-olds in the center of 
the field (p = 0.053). 6-month-old mice did not differ from the other age groups. 12-
month-old mice showed significantly greater rearing activity in the center of the field 
than 6- month-old mice (p = 0.024). This was likely due to 6-month-old mice 
spending less time in the center of the field given that they showed a trend for more 
rearing than 12-month-olds (p = 0.072) and significantly more rearing activity than 
24-month-olds (p < 0.001) in the perimeter of the open field.   
 
Assessing the contributions of α6*nAChR on anxiety-like behavior 
To assess contributions of high affinity α6*nAChRs to anxiety-like behavior, 
WT and a gain of function α6L9S mice were tested in the light-dark, marble burying 
and locomtor activity assays (Table 4).  Prior to light-dark and marble burying 
assays, mice also received injection of saline vehicle or nicotine.  
 Although most β2*nAChRs assemble with α4, within the mesolimbic and 
catecholiminergic projection pathways, the high affinity β2*nAChRs assemble with 
α6 subunits to make α6β2β3nAChRs and α6α4β2β3nAChRs. α6L9S gain of function 
mice were compared to WT mice to assess if activation of α6β2*nAChRs supports 
anxiety-like behavior in the light-dark and marble burying tasks in the presence or 
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absence of nicotine (0, 0.001, 0.0032, 0.01, 0.032, 0.1, 0.32 mg/kg i.p.). Since 
previous studies have shown that male L9S mice show a hyper-locomotor response 
to nicotine, we also assessed female mice in a locomotor assay in the presence or 
absence of nicotine.  
Light-Dark 
 There was a main effect of nicotine dose for measures latency (F6, 70  = 8.278, 
p < 0.001) (Figure 11) and percent time spent in the light chamber (F6, 70  = 3.703, p = 
0.003) (Figure 12). Consistent with previous studies showing that low doses of 
nicotine are anxiolytic and high doses are anxiogenic, post-hoc analysis revealed 
that mice receiving 0.32 mg/kg i.p. nicotine showed a significant increase in latency 
and low doses of nicotine (0.01, 0.032, and 0.1 mg/kg i.p.) resulted in significant 
decreases in latency to enter the light chamber compared to saline-injected control 
mice. Low doses of nicotine (0.01, 0.032, and 0.1 mg/kg i.p.) also resulted in 
significant elevations in the percentage of time that mice spent in the brightly lit 
chamber. This behavior was similar for WT and L9S mice, there was no effect of 
genotype on latency or time spent in the light chamber. There was also an effect of 
nicotine dose on light and dark chamber exploration as measured by movements per 
second in the light (F6, 70  = 4.378, p = 0.001) and dark (F6, 70  = 3.883, p = 0.002) 
chambers. There was a significant interaction of time bin with genotype in 
movements per second in the light chamber (F9, 360  = 2.007, p = 0.036) and a 
significant interaction of genotype with nicotine dose on movements per second in 
the dark chamber (F6, 70  = 2.475, p = 0.031). WT mice showed an inverted U pattern 
of the movements per second measure in the light and dark chambers. Low doses of 
nicotine (0.01, 0.032 and 0.1 mg/kg) stimulated exploration and the high 0.32 mg/kg 
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i.p. dose of nicotine attenuated exploration in the WT mice (p’s < 0.05). L9S mice, 
however, did not show a decline in light or dark chamber exploration at the higher 
doses.  
 
Marble Burying 
 There was a main effect of genotype (F6, 70  = 3.246, p = 0.007) for marbles 
buried. Compared to WT mice, α6L9S mice showed a significant decrease in digging 
activity, suggesting that activation of the α6β2*nAChRs promoted anxiolysis-like 
behavior in this task. There was also a main effect of dose for the measure of 
marbles buried (F1, 70  = 19.768, p < 0.001) with the highest dose of nicotine resulting 
in a significant decrease in the number of marbles buried (p = 0.03). Marble burying 
data are shown in Figure 14.  
  
Locomotor Activity 
 There was no effect of nicotine dose on locomotor activity behavior as 
measured by distance traveled or time spent immobile in the apparatus under low-
light conditions (F’s < 1.0). Unlike their male counterparts that show hyperlocomotor 
responses to nicotine (Champtiaux et al., 2002; Champtiaux et al., 2003; Cui et al., 
2003; Drenan et al., 2008; Drenan et al., 2010), female α6L9S mice did not show a 
leftward shift in distance traveled following nicotine injection. There was, however, a 
significant effect of genotype on time spent rearing with α6L9S mice showing an 
elevation in this behavior compared to WT mice (F1, 136  = 3.934, p = 0.049).  There 
was also a significant effect of nicotine dose on number of rearing events that was 
independent of genotype (F3, 136  = 4.280, p = 0.006).  The 0.032 mg/kg i.p. dose of 
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nicotine resulted in an increase in rearing activity compared to when mice had 
received saline injections.  
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Discussion 
 
The main findings of this thesis work are that β2HET and α4HET mice 
showed increased sensitivity to the antagonist di-hydrobeta-erythroidine (DHβE).  
Consistent with previous studies α4KO mice showed an anxiogenic-like phenotype 
compared to WT mice. Conversely, whilst β2KO mice failed to show significant 
changes in anxiety-like behavior compared to WT mice, these mice did show 
increased locomotor activity and exploratory behavior in the perimeter of the open 
field test, which is consistent with previous reports. Also, treatment with low doses of 
nicotine (0.01, 0.032 and 0.1 mg/kg) produced anxiolytic-like effects in WT and 
α6L9S mice, whilst a high dose of nicotine produced anxiogenic-like effects in WT 
and α6L9S mice. Activation of the α6*nAChRs supports an anxiolytic-like phenotype 
in the light-dark assay and marble burying test. Unlike male α6L9S mice, female 
α6L9S mice did not show hyperlocomotor responses to nicotine. However, female 
α6L9S mice did appear to be less sensitive than WT mice to locomotor suppressant 
effects of a high (0.32 mg/kg) dose of nicotine in the dark chamber.  
 
The nAChRs containing the α4 and β2 nAChR subunits are the most 
abundantly expressed nAChRs in the central nervous system. These receptor 
subtypes are expressed in a region specific manner in the brain and those containing 
the β2 are the most abundant in the brain (McGehee & Role, 1995). The 
α4β2*nAChRs have also been found to play a role in the anxiolytic effect of nicotine 
(Besson, Suarez, Cormier, Changeux, & Granon, 2008; King, Caldarone, & Picciotto, 
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2002; McGranahan, Patzlaff, Grady, Heinemann, & Booker, 2011). Preliminary 
studies investigating the contributions of the β2 nAChR subunit shows that 
elimination of the β2 subunit does not promote anxiolytic-like behavior in the open 
field test. There was no effect of genotype or age on center activity in the open field 
test. However, β2KO mice showed increased levels of exploration in the perimeter of 
the open field.  These results may be due to small n sizes used in these studies 
(Table 1), interpretation of these studies would benefit from replication. Although a 
null mutation for the β2 subunit did not produce an anxiety-like phenotype, in these 
studies, a loss of the α4 subunit promoted anxiogenic-like behavior. Consistent with 
previous studies using the elevated-plus maze (Ross et al., 2000) α4 Knockout 
(α4KO) female mice show increased anxiety-like behavior as shown by increased 
latency to enter the light chamber compared to heterozygous mice, decreased 
percentage of time spent in the light chamber and decreased movements per second 
in the light chamber, compared to WT mice in the light-dark assay. Taken together, 
these results suggest that α4β2*nAChRs and possibly non-β2*nAChRs such as 
α4β3 nAChRs regulate anxiety-like behavior in female mice. Further experiments are 
needed to determine the stoichiometry of the receptors involved in the behaviors 
observed.  
In contrast to α4KO mice, studies in α6L9S mice revealed that stimulation of 
α6β2*nAChRs receptors might promote anxiolysis. α6L9S mice spent more time 
rearing than WT mice in the open field, buried fewer marbles in a novel open 
chamber, and spent more time than WT mice in exploration of the light chamber, but 
not the dark chamber in the light dark assay. Together these findings suggest that 
activation of the α6*nAChRs may attenuate anxiety phenotype and promote 
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anxiolysis-like behavior in rodents. Taken together, these results suggest that 
α4β2*nAChRs and α6β2*nAChRs, possibly α4α6β2*nAChRs regulate anxiety-like 
behavior in female mice. Further experimentation in α6L9S mice crossed to α4KO 
mice could help to clarify the stoichiometry of these receptors and will establish if 
activation or inhibition of subtypes of α4α6β2*nAChRs supports anxiolysis in 
females.  
  Although genetic approaches are a useful method for assessing the role of 
genes on behavioral phenotypes, caution is needed when interpreting results. An 
important factor to consider is that alteration or deletion of a gene leads to 
compensatory mechanisms that are present over the lifetime of the animal. This 
makes it difficult to determine whether the effects observed in genetically modified 
mice are due the alteration of a gene, or if they are due to compensatory changes 
that occur during development. Another factor to consider is that knockout mice can 
pinpoint the genes that mediate the effects of a drug (e.g. nicotine). However, the 
deletion of a gene does not reveal whether variability in this gene can alter sensitivity 
to the drug investigated.  
 Another method for assessing the role of nAChRs in anxiety-like behavior 
involves pharmacological inactivation of the β2*nAChR with the selective antagonist, 
DHβE. DHβE acts on β2*nAChRs that co-assemble with other subunits to form 
α4β2, α6α4β2β3, α6β2β3 and α4α5β2nAChRs. Research has shown that DHβE 
blocks nicotine-mediated release of neurotransmitters (S. S. Khiroug, Khiroug, & 
Yakel, 2004; Lu et al., 1998; M. J. Marks et al., 2000; Whiteaker et al., 2000) and 
nicotine-elicited responses on spontaneous inhibitory postsynaptic current (IPSC) 
frequency and excitatory postsynaptic current (EPSC) in brain slices (Alkondon & 
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Albuquerque, 2002; Mansvelder, Keath, & McGehee, 2002). Therefore, the 
inactivation of β2*nAChRs by DHβE is a useful pharmacological tool to investigate 
the role β2*nAChRs play in behaviors such as anxiety that are regulated by multiple 
neurotransmitter systems. Our lab has shown that antagonism of the β2* nAChRs 
with the selective antagonist DHβE supports anxiolytic-like behavior in male C57BL/6 
mice (unpublished). These findings suggest that inactivation of these high affinity 
receptors in male mice is anxiolytic. This is the opposite of what we observed in 
C57BL/6 females in most of the present studies. 
One of the findings from these studies is that effects of DHβE on anxiety-like 
behavior in female mice appear to be age and genotype dependent. Rogers and 
colleagues have shown that aged CBAJ mice (24-28 months old) have a reduction in 
the expression of α4β2*nAChRs in key cholinergic regions in the brain (S. W. 
Rogers, Gahring, Collins, & Marks, 1998). In these studies we report that aged 
α4*nAChRs mice compared to younger mice showed decreased exploratory 
behavior and locomotor activity in the open field test. Given previous reports that the 
expression of the α4β2*nAChRs changes with age, we would expect to see changes 
in the anxiety phenotype in aged mice, however, age did not significantly affect 
anxiety-like behavior in the open field test or light-dark assay. It should be noted that 
our age groups defined in these studies did not include young adult mice. 
Interpretations of these data could benefit from the inclusion of mice which are 
younger to further assess the contributions of the β2*nAChRs on anxiety-like 
behavior across the life span in female mice. β2HET aged mice were more sensitive 
than WT aged mice to anxiogenic-like effects of DHβE treatment in the light-dark 
assay. These results further suggests that in aged mice which have a reduced 
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number of receptors due to normal aging (S. W. Rogers, Gahring, Collins, & Marks, 
1998), the further reduction of the receptors via genetic manipulation and 
subsequent inactivation of the receptors with DHβE potentiates anxiogenic-like 
behavior in aged heterozygous animals. These preliminary studies will benefit from 
replication using a more complete dose response curve for DHβE. 
In the open field test aged mice showed decreased exploratory behavior and 
locomotor activity compared to younger mice. Taken together, β2HET and α4HET 
mice show increased sensitivities to DHβE treatment, perhaps due to a decrease in 
α4* and β2*nAChR expression. This finding suggests that inhibition of β2*nAChRs 
promotes anxiogenesis in female mice. Further investigation into the relative 
expression of β2*nAChRs in the brain would further elucidate the contributions of 
region specific changes in the expression of β2*nAChRs in aged and middle aged 
mice on anxiety-like behavior. It is important to note that in the marble burying test, 
α4HET mice treated with DHβE showed anxiolytic-like effects compared to WT mice 
as measured by decreased marbles buried. Although more investigation is 
warranted, these studies overall, suggest that high affinity β2*nAChRs may be a 
useful therapeutic target for the treatment of anxiety disorders in elderly women. 
     In the marble burying test however, aged mice had decreased anxiety-like 
behavior compared to middle aged mice. Aged mice buried less marbles than did 
middle aged mice. Results from the light-dark assay and open field test were not 
consistent in the marble burying test. Although the marble burying test provides 
predictive validity through the use of anxiolytics, many believe that this test does not 
accurately measure anxiety-like behavior but is a better model for compulsive 
disorders (Jimenez-Gomez, Osentoski, & Woods, 2011; Witkin, 2008). The lack of 
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internal controls in the marble burying test makes it less effective at assessing 
anxiety-like behavior in rodents compared to the light-dark assay which possesses 
its own internal controls. Taken together, it is likely that for our experimental 
paradigm the marble burying test is not an effective method for assessing anxiety-
like behavior in female mice. To further assess anxiety-like behavior which is not 
locomotor dependent, the use of other mouse models of anxiety such as the 
conditioned emotional response assay and the potentiated acoustic startle 
paradigms would be more suitable tests as they include behavioral controls to 
assess if changes in anxiety-like behavior are learning-dependent (Davis, 1990).   
Animal research has shown that nicotine’s activity at nAChRs is dose 
dependent and doses of nicotine produces dissociate effect where low doses of 
nicotine promote anxiolytic-like effects and high doses produce anxiogenic-like 
effects on behavior (J. P. Changeux et al., 1998; File, Kenny, & Ouagazzal, 1998; 
File, Kenny, & Cheeta, 2000; Matta et al., 2007; M. R. Picciotto, Brunzell, & 
Caldarone, 2002; M. R. Picciotto, 2003; M. R. Picciotto, Addy, Mineur, & Brunzell, 
2008; Tucci, Cheeta, Genn, Seth, & File, 2002; Tucci, Cheeta, Seth, & File, 2003; 
Viveros, Marco, & File, 2006). Consistent with previous studies, effects of nicotine on 
anxiety-like behavior were dose-dependent with low doses of nicotine decreasing 
anxiety-like behavior as measured by decreased latencies to enter the light chamber 
and an increase in the percentage of time mice spent in that chamber and increased 
exploration of mice while in the light chamber. In contrast, the high dose of nicotine 
produced anxiogenic-like effects, increasing latencies to enter the light chamber, 
decreasing time spent in the light chamber, and decreasing movements per second 
in the light but not the dark chamber of the light-dark assay. Drenan and colleagues 
(2008) showed that male α6L9S mice exhibited hyperlocomotor responses to 
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nicotine when compared to WT mice. α6β2*nAChRs have a highly selective pattern 
of expression in cathecholaminergic neurons and activation of these receptor 
subtypes is necessary for nicotine’s psychostimulant effects and administration. In 
these studies, in contrast to male α6L9S mice, female α6L9S did not show an overall 
hyperlocomotor response to nicotine when compared to WT mice in the locomotor 
activity task, but did appear to be less sensitive than WT mice to locomotor 
suppressant effects of a high (0.32 mg/kg) dose of nicotine in the dark chamber. 
Together these findings suggest that activation of the α6*nAChRs may promote 
anxiolysis. An extended dose-response curve for nicotine locomotor effects will help 
establish if activation of α6*nAChRs also attenuates anxiogenic-like effects of 
nicotine.  
 
Summary 
  These studies are among the first to assess the contributions of high affinity 
nAChRs on anxiety-like behavior in female mice. Consistent with previous studies 
performed mainly in male mice, low doses of nicotine promoted anxiolysis-like 
behavior and high dose nicotine promoted anxiogenic-like behavior in the light-dark 
assay. Although a6L9S mice showed a consistent behavioral phenotype across all 
three behavioral measures (light-dark, marble burying and open field), the effects of 
nicotine and other genotypic effects did not carry-over to the marble burying test, 
suggesting that the marble burying test may not be an appropriate measure for 
assessing anxiety-like behavior in female mice in our experimental paradigms. 
Decrease in α4* and β2*nAChR expression caused increased sensitivities to DHβE 
treatment suggesting that inhibition of β2*nAChRs promotes anxiogenesis in female 
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mice. Consistent with previous studies using the elevated plus maze, α4KO female 
mice displayed an anxiogenic-like phenotype in the light-dark assay. The selective 
β2*nAChR antagonist DHβE also enhanced anxiogenic-like behavior for measures in 
this task, suggesting that inactivation of α4*nAChRs promotes anxiety-like behavior. 
In contrast, gain of function α6L9S mice showed an anxiolysis-like phenotype in the 
light-dark, locomotor, and marble burying tasks, suggesting that activation of 
α6β2*nAChRs promotes anxiolysis-like behavior in these tasks.  
 The effects observed in these studies may be mediated by sex hormones, 
however, it is currently difficult to accurately assay serum estradiol levels in female 
mice and tradition methods for carrying out vaginal smears often induce estrus. 
Therefore, without more effective methods for the assessment of hormone levels in 
female mice we cannot infer the contributions of hormones on anxiety-like behavior 
in our experimental paradigm. 
Overall, these results provide evidence that α4β2*nAChRs and α6β2*nAChRs 
regulate anxiety-like behavior in female mice. Further experimentation will help to 
clarify the stoichiometry of these receptors and will establish if activation or inhibition 
of subtypes of β2*nAChRs supports anxiolysis in females. These experiments 
provide possible therapeutic targets for the treatment of anxiety disorders in women.  
 
Future Directions 
     It is important to consider the intricate interplay of regionally specific nAChR 
expression, the nature of the specific behavioral test used, and the physiological 
responses to identify genetic contributions on anxiety-like behavior. To further 
assess the neuroanatomical changes involved in the changes in anxiety-like 
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behavior observed in these studies, identification and quantification of the nAChRs 
subtypes present in key brain regions associated with anxiety would aid in 
elucidating the molecular changes associated with the age-dependent effects on 
behavior. Pending the availability of selective antibodies as tools, Western Blot 
analysis will provide information on the molecular changes in our experimental 
paradigm. To further elucidate which subtype of high affinity nAChRs are involved in 
anxiety-like behavior, the use of genetically manipulated mice strains such as 
crosses of α4KO mice with α6L9S mice or assessing the behavior of α6KO mice 
would further allow investigation of receptor stoichiometry involved in the behaviors 
found in these studies.   
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Tables 
 
Table 1. n sizes for mice in genotypic studies of anxiety-like behavior.  
Behavioral test Light-dark Marble burying 
Genotype Treatment 
Age 
12 24 12 24 
WT (β2) 
SAL 5 6 4 6 
DHβE 4 6 5 6 
β2HET 
SAL 2 4 3 3 
DHβE 3 4 3 4 
β2KO 
SAL 5 7 6 7 
DHβE 6 8 6 8 
WT (α4) 
SAL 9 7 9 8 
DHβE 9 10 9 9 
α4HET 
SAL 10 4 10 5 
DHβE 9 3 10 3 
α4KO 
SAL 9 3 9 2 
DHβE 9 3 9 3 
Treatment groups include saline (SAL) and di-hydrobeta-erythroidine (DHβE). 
Genotypes include β2 knockout (β2KO), β2 heterozygous (β2HET), and wild type 
littermates (WT (β2)), α4 knockout (α4KO), α4 heterozygous (α4HET) and wild type 
littermates (WT (α4)).  
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Table 2. Open field experiment n sizes for wild type (WT), β2 heterozygous (β2HET) 
and β2 knockout (β2KO) mice. 
Behavioral test Open field 
Genotype 
Age 
12 24 
WT 15 19 
β2HET 11 11 
β2KO 18 20 
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Table 3. Open field experiment n sizes for wild type (WT), α4 heterozygous (α4HET) 
and α4 knockout (α4KO) mice.   
Behavioral test Open field 
Genotype 
Age 
6 12 24 
WT 11 15 11 
α4HET 13 14 14 
α4KO 12 19 11 
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Table 4. Average age in months for wild type (WT) and α6L9S (L9S) transgenic 
mice. 	  
Genotype 
Nicotine Dose (mg/kg; i.p.) 
0 0.001 0.0032 0.01 0.032 0.1 0.32 
WT 8.1±1 (6) 
7.9±0.8 
(6)  
7.8±0.5 
(6) 
8.0±0.9 
(6) 
8.1±1 
(6) 
7.9±1 
(6) 
7.9±0.9 
(6) 
L9S 7.6±0.7  (6) 
8.2±0.7 
(6) 
7.7±0.5 
(6) 
6.2±0.6 
(6) 
7.0±0.6 
(6) 
6.6±0.4 
(6) 
7.4±0.7 
(6) 
Data are represented as Mean ± SEM; n sizes are depicted in parenthesis. 
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Figures 
 
Figure 1. Light- dark activity of 12-month-old and 24-month-old wild type mice (WT), 
β2*nAChR knockout mice (β2KO) and β2*nAChR heterozygous mice (β2HET) on 
measures of latency to enter the light chamber and percentage of time spent in the 
light chamber. There was no effect of genotype or di-hydrobeta-erythroidine (DHβE) 
treatment or age or interaction of genotype by age by treatment on measures of 
light-dark activity. Data are expressed as mean ± SEM; (n = 2-8 per group). 
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Figure 2. Light-dark activity of 12-month-old and 24-month-old wild type mice (WT), 
β2*nAChR knockout mice (β2KO) and β2*nAChR heterozygous mice (β2HET) on 
measures of movement per second in the light and dark chambers. There was a 
significant effect of time bin by genotype by di-hydrobeta-erythroidine (DHβE) 
treatment in the light chamber of the light-dark assay. No effect of genotype, 
treatment or age or an interaction of genotype by age by treatment on movements 
per second in the dark chamber. Data expressed as mean ± SEM; p  = 0.008 (n = 
2-8 per group). 
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Figure 3. Light-dark  activity of 12-month-old and 24-month-old wild type mice (WT), 
β2*nAChR knockout mice (β2KO) and β2*nAChR heterozygous mice (β2HET) on 
measures of movement per second in the light and dark chambers. 24-month-old 
β2HET mice treated with di-hydrobeta-erythroidine (DHβE) had significantly reduced 
movement/sec in the light chamber at 1-5 minutes compared to 24-month-old WT 
mice treated with DHβE. No significant effect of genotype, treatment or age was 
found in the dark chamber or at 6-10 minutes in both chambers. Data are expressed 
as mean ± SEM; *p  < 0.05 compared to WT controls of the same drug treatment; 
(n = 2-8) 
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Figure 4. Marble burying activity of 12-month-old and 24-month-old wild type mice 
(WT), β2*nAChR knockout mice (β2KO) and β2*nAChR heterozygous mice 
(β2HET). Compared to 12-month-old WT mice, 12-month-old β2HET mice buried a 
significantly more marbles. There was no effect of di-hydrobeta-erythroidine (DHβE) 
treatment or interaction of genotype by age by treatment on measures of marble 
burying activity. Data are expressed as mean ± SEM; *p  < 0.05 compared to WT 
controls (n = 3-7 per group). 
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Figure 5. Open field activity of 12-month-old and 24-month-old wild type mice (WT), 
β2*nAChR knockout mice (β2KO) and β2*nAChR heterozygous mice (β2HET) on 
measures of distance traveled, time spent and rearing in the center and perimeter of 
the open field arena. A) Compared to WT mice, β2KO but not β2HET mice travelled 
a significantly greater distance in the perimeter of the open field. There was no effect 
of genotype on B) distance traveled in the center of the arena, on C, D) time spent in 
the perimeter or the center, or on F) rearing in the center of the open field. E) 
Similarly to distance traveled, β2KO mice showed a significant increase in 
exploration of the perimeter as measured by elevated levels of rearing compared to 
WT mice. There was no effect of age or interaction of genotype with age on 
measures of open field activity. Data are expressed as mean ± SEM; *p  < 0.05 
compared to WT controls (n = 11-20 per group). 
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Figure 6. Light-dark activity of 12-month-old and 24-month-old wild type mice (WT), 
α4*nAChR knockout mice (α4KO) and α4*nAChR heterozygous mice (α4HET) on 
measures of latency to enter the light chamber. A) Compared to WT mice, α4KO but 
not α4HET mice latency to enter the light chamber was significantly greater. Similarly 
treatment with di-hydrobeta-erythroidine (DHβE) B) significantly increased the 
latency to enter the light chamber compared to saline (SAL) treated mice. No effect 
of age or interaction of age by genotype by treatment on measures of light-dark 
activity. Data are expressed as mean ± SEM; *p  < 0.05 compared to WT; **p  < 
0.05 compared to drug controls (n = 3-10 per group). 
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Figure 7. Light-dark activity of 12-month-old and 24-month-old wild type mice (WT), 
α4*nAChR knockout mice (α4KO) and α4*nAChR heterozygous mice (α4HET) on 
measures of percentage of time spent in the light chamber. A) Compared to WT 
mice, α4KO but not α4HET mice spent a significantly decreased percentage of time 
in the light chamber. Similarly treatment with di-hydrobeta-erythroidine (DHβE) B) 
significantly decreased the latency to enter the light chamber compared to saline 
(SAL) treated mice. No effect of age or interaction of age by genotype by treatment 
on measures of light-dark activity. Data are expressed as mean ± SEM; *p  < 0.05 
compared to WT; **p  < 0.05 compared to drug controls; (n = 3-10 per group). 
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Figure 8. Light-dark activity of 12-month-old and 24-month-old wild type mice (WT), 
α4*nAChR knockout mice (α4KO) and α4*nAChR heterozygous mice (α4HET) on 
measures of movement per second in the light and dark chambers. A) Compared to 
WT, α4KO but not α4HET mice had decreased movement per second in the light 
chamber compared to WT mice and B) increased movement per second in the dark 
chamber compared to WT mice. Data are expressed as mean ± SEM; *p  < 0.05 
compared to WT controls; **p  < 0.01 compared to drug controls  (n = 3-10 per 
group). 
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Figure 9. Marble burying activity of 12-month-old and 24-month-old wild type mice 
(WT), α4*nAChR knockout mice (α4KO) and α4*nAChR heterozygous mice 
(α4HET). A) Antagonism with di-hydrobeta-erythroidine (DHβE) significantly reduced 
the number of marbles buried in α4HET mice but not α4KO compared to WT mice. 
B) 24-month-old mice buried significantly less marbles than 12-month-old mice. Data 
are expressed as mean ± SEM; *p  < 0.05 compared to 12-month-old controls; **p  
< 0.01 compared to 12-month-old; (n = 2-10 per group). 
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Figure 10. Open field activity of 6-month-old, 12-month-old and 24-month-old wild 
type mice (WT), α4*nAChR knockout mice (α4KO) and α4*nAChR heterozygous 
mice (α4HET) on measures of distance traveled, time spent and rearing in the center 
and perimeter of the open field arena.  A) Compared to 6-month-old mice, 24-month-
old but not 12-month-old mice travelled a significantly greater distance in the 
perimeter of the open field. B) Similarly 24-month-old mice and 12-month-old mice 
greater distance compared to 6-month-old mice in the center of the arena. There 
was no effect of genotype on C) time spent in the perimeter of the open field. D) A 
trend for 12-month-old mice to spent increased time in the center of the arena 
compared to 24-month old mice in the center of the open field arena. E) 24-month-
old mice reared significantly longer than did 6-month-old mice in the perimeter of the 
open field arena F) 12-month-old mice reared significantly longer than did 6-month-
old mice in the center of the open field arena. There was no effect of genotype or 
interaction of genotype with age on measures of open field activity. Data are 
expressed as mean ± SEM; *p  < 0.05 compared to 6-month-old controls, **p  < 
0.01 compared to 6-month-old controls, ***p  < 0.001 compared to 6-month-old 
controls; ψ p  = 0.053 compared to 12-month-old; (n = 11-20 per group). 
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Figure 11. Light- dark activity of wild type mice (WT) and α6L9S nAChR mice (L9S) 
on measures of latency to enter the light chamber. Low doses of nicotine (0.01, 
0.032 and 0.1 mg/kg, i.p.) significantly reduced latencies to enter the light chamber 
compared to saline. In contrast a high dose of nicotine (0.32 mg/kg; i.p.) significantly 
increased latency to enter the light chamber compared to saline treated mice. Data 
are expressed as mean ± SEM; *p  < 0.05 compared to 6-month-old controls, *p  < 
0.05 compared to saline control; (n = 6 per group). 
 
 
 
 
 
 
 
 
 
  
 
71 
 
 
Figure 12. Light- dark activity of wild type mice (WT) and α6L9S nAChR mice (L9S) 
on measures of percentage of time spent in the light chamber. Low doses of nicotine 
(0.01, 0.032 and 0.1 mg/kg, i.p.) significantly increased time spent in the light 
chamber compared to saline. In contrast a high dose of nicotine (0.32 mg/kg; i.p.) 
significantly decreased time spent in the light chamber compared to saline treated 
mice. Data are expressed as mean ± SEM; *p  < 0.05 compared to 6-month-old 
controls, *p  < 0.05 compared to saline control; (n = 6 per group). 
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Figure 13. Light- dark activity of wild type mice (WT) and α6L9S nAChR mice (L9S) 
on measures of movement per sec in the light and dark chambers. A) Low doses of 
nicotine (0.01, 0.032 and 0.1 mg/kg, i.p.) significantly increased movements per sec 
in the light chamber compared to saline. In contrast a high dose of nicotine (0.32 
mg/kg; i.p.) significantly reduced movements per sec in the light chamber compared 
to saline treated mice. B) WT mice treated with a high dose of nicotine showed 
reduced movements per sec in the dark chamber compared to saline treated WT 
mice. Data are expressed as mean ± SEM; *p  < 0.05 compared to saline, **p  < 
0.05 compared to WT drug control; (n = 6 per group). 
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Figure 14. Marble burying activity of wild type mice (WT) and α6L9S nAChR mice 
(L9S) on measures of marbles buried. A) A high dose of nicotine (0.32 mg/kg; i.p.) 
significantly reduced the number of marbles buried compared to saline treated mice. 
B) L9S mice buried significantly less marbles than WT. Data are expressed as mean 
± SEM; *p  < 0.05 compared to saline, ***p  < 0.01 compared to WT mice; (n = 6 
per group). 
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Figure 15. Locomotor activity of wild type mice (WT) and α6L9S nAChR mice (L9S) 
on measures of distance traveled, time immobile, rearing and time spent rearing in 
the locomotor activity apparatus. No effect of nicotine dose on locomotor activity 
measures of A) distance traveled in the apparatus or C) time spent immobile. B) A 
low dose of nicotine (0.0032 mg/kg, i.p.) significantly increased the number or 
rearing behavior compared to saline treated mice. D) L9S mice spent more time 
rearing than did WT mice. No effect of genotype or interaction of genotype by 
treatment on measures of locomotor activity. Data are expressed as mean ± SEM; 
**p  < 0.01 compared to saline, *p  < 0.05 compared to WT mice; (n = 6 per group). 
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